Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Preventive treatment with Takhzyro (lanadelumab) significantly reduces the number of swelling attacks in people with hereditary angioedema (HAE), even in the early phases of treatment, a post hoc analysis from the ... Read more
Preventive treatment with Takhzyro (lanadelumab) is effective at delaying and lowering the monthly rate of attacks in a broad range of patients with hereditary angioedema (HAE), a study has ... Read more
After showing a sustained reduction in kallikrein levels in animal models, Intellia Therapeutics will be moving forward with the development of its gene-editing candidate NTLA-2002 for the treatment of hereditary angioedema ... Read more
A small molecule inhibitor being developed for hereditary angioedema (HAE) treatment, called PHA121, was as effective as Firazyr (icatibant acetate) — an approved therapy with a similar mechanism of action — at ... Read more
The European Medicines Agency has validated BioCryst Pharmaceuticals‘ application requesting the approval of berotralstat as a once-daily oral treatment to prevent swelling attacks in people with hereditary angioedema (HAE). The Committee ... Read more
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended Ruconest (conestat alfa) for approval as treatment for acute swelling episodes in children with hereditary angioedema (HAE). ... Read more
Patients who experience an angioedema attack during treatment with angiotensin-converting enzyme inhibitors — a kind of medication for high blood pressure and heart failure — may safely switch to a ... Read more
Takhzyro (lanadelumab), a kallikrein inhibitor by Shire, has been approved in Europe for the routine prevention of hereditary angioedema (HAE) attacks in patients ages 12 and older, making it the first antibody available in ... Read more
Routine treatment with Shire‘s Takhzyro (lanadelumab) — given as a 300 mg dose every two weeks — significantly reduces the rate of acute attacks in hereditary angioedema (HAE) patients age 12 ... Read more
The U.S. Food and Drug Administration recently approved Shire’s Cinryze (C1 esterase inhibitor ) to help prevent angioedema attacks in children 6 and older who live with hereditary angioedema (HAE). ... Read more
Pin It on Pinterest